Filter Results:
(1,246)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (931)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (931)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- December 2000 (Revised January 2001)
- Background Note
Promise of Functional Foods, The
By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock
This case presents a definition of functional foods or nutraceuticals (food or food ingredients that could provide a health benefit beyond the traditional nutrients they contain), a description of some of the major obstacles to their commercialization and... View Details
Keywords: Food; Private Sector; Public Sector; Health; Product Development; Production; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Laure Mougeot Stroock. "Promise of Functional Foods, The." Harvard Business School Background Note 901-013, December 2000. (Revised January 2001.)
- April 2008 (Revised May 2009)
- Case
Robert Wessman and Actavis' "Winning Formula"
Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with 11,000 people, active in 40 countries, global manufacturing, and $1.6 billion.... View Details
Keywords: Globalized Firms and Management; Business Growth and Maturation; Success; Transformation; Business Strategy; Pharmaceutical Industry; Iceland
Isenberg, Daniel J. Robert Wessman and Actavis' "Winning Formula". Harvard Business School Case 808-127, April 2008. (Revised May 2009.)
- 22 Sep 2015
- News
Should Bank of America's CEO also be the chairman?
- 17 May 2016
- News
What Is The Most Important Innovation in American History?
- Video
Said Darwazah
Said Darwazah, Executive Chairman and CEO of Hikma Pharmaceuticals PLC, speaks about the importance of hiring local employees to help lead the company’s expansions into new markets, particularly in the context of political crises such as the Arab Spring or health... View Details
- April 2014
- Case
Merrimack Pharmaceuticals, Inc. (A)
By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R＆D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
- July 2010
- Case
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details
Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States
Quelch, John A., and Heather Beckham. "Metabical: Positioning and Communications Strategy for a New Weight Loss Drug." Harvard Business School Brief Case 104-240, July 2010.
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- October 2012
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
By: Toby Stuart and James Weber
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and James Weber. "Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)." Harvard Business School Case 813-029, October 2012.
- March 2008 (Revised June 2008)
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
- June 2004
- Case
Aventis SA (A): Planning for a Merger
By: Joshua D. Margolis and Carin-Isabel Knoop
Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must... View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (A): Planning for a Merger." Harvard Business School Case 404-003, June 2004.
- Research Summary
Research Interests
Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details
- July 1989 (Revised December 1990)
- Case
CIBA-GEIGY Pharmaceuticals: Pharma International
By: John A. Quelch
Examines the decision by Pharma International on whether to launch an antimalarial product in Nigeria and, if so, how that should be implemented. Involves commercial, ethical, and policy considerations. Rich in situation assessment data, the case refers to criticism of... View Details
Keywords: Ethics; Decision Choices and Conditions; Product Launch; Policy; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Quelch, John A. "CIBA-GEIGY Pharmaceuticals: Pharma International." Harvard Business School Case 589-108, July 1989. (Revised December 1990.)
- December 2008 (Revised April 2010)
- Case
Proteus Biomedical: Making Pigs Fly
By: Richard G. Hamermesh, Lauren Barley and Ginger Graham
Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is... View Details
Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., Lauren Barley, and Ginger Graham. "Proteus Biomedical: Making Pigs Fly." Harvard Business School Case 809-051, December 2008. (Revised April 2010.)
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R＆D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Corporate Governance; Investment Activism; Business and Stakeholder Relations; Business Model; Business and Shareholder Relations; Valuation; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
- January 2016 (Revised January 2019)
- Case
The Allergan Board Under Fire (A)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R＆D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Management Teams; Business and Shareholder Relations; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.)
- November 2019 (Revised April 2020)
- Technical Note
The Life Sciences Revolution: A Technical Primer
By: Gary P. Pisano, William J. Anderson, Amitabh Chandra, Clarissa Ceruti and Stephanie Oestreich
For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be... View Details
Keywords: Science; Technological Innovation; Technology; Pharmaceutical Industry; Pharmaceutical Industry
Pisano, Gary P., William J. Anderson, Amitabh Chandra, Clarissa Ceruti, and Stephanie Oestreich. "The Life Sciences Revolution: A Technical Primer." Harvard Business School Technical Note 620-054, November 2019. (Revised April 2020.)
- January 2001
- Case
Merck Global Health Initiatives (B): Botswana
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
Keywords: Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Africa; Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (B): Botswana." Harvard Business School Case 301-089, January 2001.
- 15 Feb 2018
- News